Concepedia

Author

Michael Rytting

The University of Texas MD Anderson Cancer Center

Also Known As

M Rytting, M. E. Rytting, M. Rytting, Michael E Rytting, Michael E. Rytting, Michael Rytting, Rytting, Michael E., S. Dasgupta

145

Publications

6.3K

Citations

36

H-Index

49

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterSt. Jude Children's Research HospitalMemorial Sloan Kettering Cancer CenterThe University of Texas Health Science Center at HoustonChildren's Hospital of Los Angeles
MR

About

Michael Rytting is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

18

1.4K

2

Health Sciences

6

6

359

3

Immunology

6

6

829

4

Cell Biology

2

2

193

5

Cellular Therapies

1

1

167

Michael Rytting

×

55

Publications

5.1K

Citations

34

H-Index

YearCitations

Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

Guillermo Garcia‐Manero, Hagop M. Kantarjian, Blanca Sánchez‐González,

Blood

2006

467

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen,

The Lancet Oncology

2012

410

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Nitin Jain, Audrey Lamb, Susan O’Brien,

Blood

2016

338

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia

Sima Jeha, Paul S. Gaynon, Bassem I. Razzouk,

Journal of Clinical Oncology

2006

304

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen,

Cancer

2013

298

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

Sima Jeha, Varsha Gandhi, Ka Wah Chan,

Blood

2003

231

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

Wendy Stock, Dan Douer, Daniel J. DeAngelo,

Leukemia & lymphoma/Leukemia and lymphoma

2011

228

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Naval Daver, Deborah A. Thomas, Farhad Ravandi,

Haematologica

2015

220

Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with <scp>P</scp>hiladelphia chromosome–positive acute lymphoblastic leukemia

Farhad Ravandi, Susan O’Brien, Jörge E. Cortes,

Cancer

2015

216

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Francesco Paolo Tambaro, Harjeet Singh, Emily Jones,

Leukemia

2021

167

Page 1